Tiliroside

Tiliroside has been identified as the primary bioactive flavonoid in linden flower by multiple European research groups using HPLC-MS profiling. Animal studies demonstrate anti-obesity, lipid-lowering, and anti-inflammatory effects in diet-induced obesity models. In vitro studies confirm PPARα activation and NF-κB inhibition at physiologically relevant concentrations. Limited human pharmacokinetic data exist, but absorption and metabolite profiles have been characterised in plasma after oral consumption of linden flower tea by healthy volunteers.

Tiliroside's PPARγ agonist activity has been characterized in adipocyte cell culture models and in high-fat diet obese mouse models, demonstrating significant improvements in insulin sensitivity, lipid profile, and body weight. Anti-inflammatory activity has been confirmed in multiple in vitro and rodent models at pharmacologically relevant doses. Direct clinical human trials specifically for tiliroside from linden are lacking; evidence is primarily preclinical with mechanistic plausibility for the traditional uses.